Are pharmacokinetic drug interactions with the SSRIs an issue?

International Clinical Psychopharmacology

Volumn 11, Issue SUPPL. 1, 1996, Pages 23-27

  Brosen K ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Cytochrome P450; Drug interactions; Drug oxidation; Genetic polymorphism; SSRI

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CITALOPRAM FLUVOXAMINE; CYTOCHROME P450 ISOENZYME; DRUG METABOLIZING ENZYME; FLUOXETINE; HORMONE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PAROXETINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG INTERACTION; DRUG OXIDATION; ENZYME INHIBITION; GENETIC POLYMORPHISM; HUMAN; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS; CITALOPRAM; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FLUOXETINE; FLUVOXAMINE; HUMANS; LIVER; SEROTONIN UPTAKE INHIBITORS;

EID: 0029928537     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199603001-00005     Document Type: Article

References (9)

1. Brøsen K (1993) The pharmacogenetics of the selective serotonin reuptake inhibitors. Clinical Investigator, 71, 1002-1009.
2. Brøsen K and Gram LF (1989) The clinical relevance of the sparteine/debrisoquine oxidation polymorphism. European Journal of Clinical Pharmacology, 36, 537-547.
3. Brøsen K, Gram LF and Kragh-Sørensen P (1991) Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine and mephenytoin. Therapeutic Drug Monitoring, 13, 177-182.
4. Brøsen K, Hansen JG, Nielsen KK, Sindrup SH and Gram LF (1993a) Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. European Journal of Clinical Pharmacology, 44, 349-355.
5. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE and Loft S (1993b) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochemical Pharmacology, 45, 1211-1214.
6. Brøsen K, de Morais SMF, Meyer UA and Goldstein J (1995) A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics, 5, in press.
7. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA and Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. Journal of Biological Chemistry, 269, 15419-15422.
8. Heim M and Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet, 336, 529-532.
9. Rasmussen BB, Mäenpäee J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J and Brøsen K (1995) Selective serotonin reuptake inhibitors and theophyline metabolism in human liver microsomes: potent inhibition by fluvoxamine. British Journal of Clinical Pharmacology, 39, 151-159.